Evidence map›Paper›PMID 42559411›Full record

ArticleTheranostics2026

An engineered ferritin nanocage co-delivery system for targeted hair cells protection and hearing loss attenuation.

Junying Zhang, Zhiwei Zheng, Jiaru Zhang, Xinyuan Ma, Zihao Li, Hongyan Lin, Guohui Nie, Minmin Liang, Hui Ding, Yingzi He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Junying ZhangENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, P. R. China.
Zhiwei ZhengENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, P. R. China.
Jiaru ZhangDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P. R. China.
Xinyuan MaSchool of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Zihao LiSchool of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Hongyan LinSchool of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Guohui NieDepartment of Otolaryngology and Institute of Translational Medicine, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, P. R. China.
Minmin LiangExperimental Center of Advanced Materials, School of Materials Science & Engineering, Beijing Institute of Technology, Beijing, P. R. China.
Hui DingDepartment of Otolaryngology and Institute of Translational Medicine, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, P. R. China.
Yingzi HeENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Hearing loss is a common sensory disorder with few treatment options, mainly due to the blood-labyrinth barrier and lack of effective targeted delivery systems. Small molecules such as LLY283 and RG108 protect hair cells (HCs), but clinical use is limited by poor cellular uptake, off-target toxicity, and inefficient cochlear delivery. Methods: We developed a ferritin (Fn)-based nanocage (LR@Fn) to co-deliver RG108 and LLY283 via local injection through the round window membrane. Fn offers natural HC targeting, a hollow cavity, and good biocompatibility. Drugs were loaded using a pH-triggered strategy while maintaining structural and colloidal stability. Results: In neonatal cisplatin and adult noise-induced hearing loss models, LR@Fn reduced HCs loss, synaptic damage, and apoptosis more effectively than dexamethasone. LR@Fn treatment activated the Conclusions: LR@Fn is a biocompatible ferritin-based platform for targeted inner-ear therapy, showing potential for multiple forms of hearing loss.

Indexed as

Drug Delivery SystemsFerritinsHair Cells, AuditoryHearing LossAnimalsApoptosisCisplatinDisease Models, AnimalHumansMiceCisplatinFerritinsdrug deliveryferritinhair cellshearing lossnanomedicine

Identifiers

PMID42559411
PMCPMC13440433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.